Introduction

Kynurenine Pathway In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

flowchart TD
    A["Tryptophan"]  -->  B["IDO/TDO"]

    B  -->  C["1Tryptophan Degradation"]
    C["1"] -->  D["1Kynurenine"]

    D["1"] -->  E["1Kynurenine 3-Monooxygenase"]
    D["1"] -->  E["2Kynureninase"]
    D["1"] -->  E["3Aminocarboxymuconate Semialdehyde"]

    E["1"] -->  F["13-Hydroxyanthranilic Acid"]
    E["2"] -->  F["23-Hydroxykynurenine"]
    E["3"] -->  F["3Quinolinic Acid"]

    F["2"] -->  G["13-Hydroxyanthranilic Acid"]
    F["1"] -->  G1

    G["1"] -->  H["1NAD+ Synthesis"]
    F["3"] -->  H1

    F["2"] -->  I["1Free Radical Generation"]
    F["3"] -->  I["2NMDA Receptor Agonist"]

    I["1"] -->  J["1Oxidative Stress"]
    I["2"] -->  J["2Excitotoxicity"]
    J["1"] -->  K["1Neurotoxicity"]
    J["2"] -->  K1

    H["1"] -->  L["1Cellular Energy"]

    style A fill:#9ff,stroke:#333
    style K1 fill:#3b1114,stroke:#333
    style L1 fill:#9f9,stroke:#333

Overview

The kynurenine pathway (KP) is the principal catabolic route for the essential amino acid tryptophan, accounting for approximately 95% of tryptophan degradation in the body. This metabolic cascade generates a series of neuroactive intermediates—collectively termed kynurenines—that exert profound effects on the central nervous system through modulation of glutamate neurotransmission, oxidative stress, neuroinflammation, and immune signaling. Dysregulation of the kynurenine pathway has been increasingly implicated in the pathogenesis of alzheimers, parkinsons, huntington-pathway, als, and multiple-sclerosis, making it a compelling target for neuroprotective therapeutic intervention. ^{1Citation2025Open reference}

The pathway produces both neuroprotective metabolites (kynurenic acid) and neurotoxic metabolites (quinolinic acid, 3-hydroxykynurenine), and the balance between these branches—governed by cell type-specific enzyme expression in astrocytes and [microglia" title=“Kynurenine Pathway: a possible new mechanism for exercise in the prevention and treatment of Alzheimer’s Disease. Front Aging Neurosci (2025. Frontiers)”>2. ^{2Citation2022Open reference}

• Indoleamine 2,3-dioxygenase 2 (IDO2): Lower catalytic activity than IDO1; expressed in liver, kidney, and brain with a less well-characterized role in neurodegeneration.

• Tryptophan 2,3-dioxygenase (TDO2): Constitutively expressed in the liver and brain; regulated by tryptophan availability and glucocorticoids. TDO2 is upregulated in the hippocampus and cortex of Alzheimer’s Disease brains, contributing to local kynurenine production ^{2Citation2022Open reference}.

N-formylkynurenine is rapidly converted to L-kynurenine by kynurenine formamidase. L-kynurenine then serves as the central branch point of the pathway. ^{3'Dynamic changes in metabolites of the kynurenine pathway in Alzheimer''s Disease, Parkinson''s Disease, and Huntington''s Disease: A systematic review and meta-analysis. *Front Immunol* (2022).2022Open reference}

The Neuroprotective Branch: Kynurenic Acid

L-kynurenine is transaminated by kynurenine aminotransferases (KATs I–IV) to produce kynurenic acid (KYNA). This metabolite is predominantly synthesized by astrocytes and acts as ^{3'Dynamic changes in metabolites of the kynurenine pathway in Alzheimer''s Disease, Parkinson''s Disease, and Huntington''s Disease: A systematic review and meta-analysis. *Front Immunol* (2022).2022Open reference}: ^{4Citation2022Open reference}

• An endogenous antagonist of nmda-receptor receptor] receptors] at the glycine co-agonist site, providing protection against excitotoxicity

• An antagonist of the α7 nicotinic acetylcholine receptor, modulating cholinergic neurotransmission

• A ligand of the aryl hydrocarbon receptor (AHR), influencing immune regulation

• An antioxidant that scavenges reactive oxygen species

KYNA levels are generally reduced in neurodegenerative diseases, reflecting a shift of the pathway toward the neurotoxic branch ^{3'Dynamic changes in metabolites of the kynurenine pathway in Alzheimer''s Disease, Parkinson''s Disease, and Huntington''s Disease: A systematic review and meta-analysis. *Front Immunol* (2022).2022Open reference4Citation2022Open reference}. ^{5Citation2025Open reference}

The Neurotoxic Branch: 3-Hydroxykynurenine and Quinolinic Acid

The alternative metabolic route involves hydroxylation of L-kynurenine by kynurenine 3-monooxygenase (KMO) to yield 3-hydroxykynurenine (3-HK). This pathway proceeds predominantly in microglia^{5Citation2025Open reference}: ^{2Citation2022Open reference}0

• 3-Hydroxykynurenine (3-HK): A potent generator of reactive oxygen species through auto-oxidation. 3-HK induces neuronal apoptosis via oxidative stress mechanisms, damages mitochondrial-dynamics, and enhances vulnerability to excitotoxic insult ^{2Citation2022Open reference}1.

• 3-Hydroxyanthranilic acid (3-HAA): Downstream metabolite of 3-HK via kynureninase; has both pro-oxidant and immunomodulatory properties. 3-HAA inhibits T cell proliferation and induces apoptosis in immune cells ^{2Citation2022Open reference}2.

• Quinolinic acid (QUIN): The terminal neurotoxic metabolite, produced from 3-HAA by 3-hydroxyanthranilic acid oxygenase (3-HAO). Quinolinic acid is a selective agonist of nmda-receptor receptor] receptors] containing GluN2A and GluN2B subunits, causing excitotoxic neuronal damage. QUIN also promotes tau] hyperphosphorylation], generates reactive oxygen species, inhibits glutamate uptake by astrocytes, and disrupts the blood-brain-barrier ^{2Citation2022Open reference}3.

Cell-Type Specificity

A critical feature of the kynurenine pathway in the brain is its cell-type compartmentalization: ^{2Citation2022Open reference}4

• astrocytes express KATs but lack KMO, preferentially producing neuroprotective KYNA

• **microglia" title=“Tryptophan Metabolism and Neurodegeneration: Longitudinal Associations of Kynurenine Pathway Metabolites with Cognitive Performance and Plasma AD Biomarkers. J Alzheimers Dis (2023. PubMed)”>8

In Down syndrome-associated Alzheimer’s Disease, kynurenine pathway metabolite alterations have also been documented, with elevated QUIN/KYNA ratios correlating with cognitive decline ^{2Citation2022Open reference}5. ^{2Citation2022Open reference}6

Parkinson’s Disease

In parkinsons, kynurenine pathway dysregulation contributes to dopaminergic-neurodegeneration: ^{2Citation2022Open reference}7

• 3-HK and QUIN promote oxidative damage in [dopaminergic neurons[neurons inflammatory signatures in ALS tissue ^{2Citation2022Open reference}8

Therapeutic Targeting

KMO Inhibitors

Kynurenine 3-monooxygenase (KMO) is the most actively pursued therapeutic target within the kynurenine pathway. Inhibiting KMO: ^{2Citation2022Open reference}9

• Blocks formation of neurotoxic 3-HK and downstream QUIN

• Shunts kynurenine metabolism toward neuroprotective KYNA production

• Brain-penetrant KMO inhibitors have shown efficacy in preclinical models of HD, AD, and stroke ^{2Citation2022Open reference}0

Several classes of KMO inhibitors have been developed: ^{2Citation2022Open reference}1

• Ro 61-8048: Early prototype that demonstrated neuroprotection in HD mouse models but has limited brain penetrance

• CHDI-340246: Optimized for brain exposure; reduces 3-HK and elevates KYNA in rodent brains

• GSK065/GSK366: Clinical-stage KMO inhibitors developed for peripheral indications, with potential repurposing for neurodegeneration ^{2Citation2022Open reference}2^{2Citation2022Open reference}3

IDO1 Inhibitors

IDO1 inhibitors, originally developed for immuno-oncology (e.g., epacadostat, navoximod), could theoretically reduce overall kynurenine pathway flux during neuroinflammation. However, their application in neurodegeneration is complicated by IDO1’s dual role in immune regulation—inhibiting IDO1 may exacerbate autoimmune components of disease ^{2Citation2022Open reference}4. ^{2Citation2022Open reference}5

KYNA Analogs and Prodrugs

Strategies to boost neuroprotective KYNA include: ^{2Citation2022Open reference}6

• Synthetic KYNA analogs with improved Blood-Brain Barrier penetrance

• KAT enzyme activators to enhance endogenous KYNA production

• Prodrug approaches that release KYNA in brain tissue ^{2Citation2022Open reference}7

Exercise as a Therapeutic Modality

Physical exercise acts as a “kynurenine sink” through induction of kynurenine aminotransferases (KATs) in skeletal muscle. Exercise-induced KAT expression: ^{2Citation2022Open reference}8

• Converts circulating kynurenine to KYNA in the periphery

• Reduces brain kynurenine uptake (kynurenine crosses the Blood-Brain Barrier; KYNA does not)

• Mitigates excitotoxicity and neuroinflammation centrally

• May partly explain the neuroprotective effects of exercise in neurodegenerative diseases ^{2Citation2022Open reference}9

Kynurenine Pathway and Cerebral Small Vessel Disease

Recent evidence from the Maastricht Study (2025) links kynurenine pathway metabolites to markers of neurodegeneration and cerebral-small-vessel-disease. Higher kynurenine/tryptophan ratios and elevated 3-HK are associated with white matter hyperintensities and brain atrophy, suggesting that KP dysregulation may contribute to vascular-dementia pathogenesis through endothelial damage and blood-brain-barrier dysfunction ^{3'Dynamic changes in metabolites of the kynurenine pathway in Alzheimer''s Disease, Parkinson''s Disease, and Huntington''s Disease: A systematic review and meta-analysis. *Front Immunol* (2022).2022Open reference}0. ^{3'Dynamic changes in metabolites of the kynurenine pathway in Alzheimer''s Disease, Parkinson''s Disease, and Huntington''s Disease: A systematic review and meta-analysis. *Front Immunol* (2022).2022Open reference}1

Future Directions

Key research priorities include:

• Development of brain-penetrant KMO inhibitors suitable for chronic dosing in neurodegenerative diseases

• Validation of KP metabolites (QUIN/KYNA ratio, 3-HK levels) as prognostic biomarkers across disease stages

• Understanding the interaction between gut microbiome-derived tryptophan metabolites and brain KP activity

• Elucidation of the role of the AHR (aryl hydrocarbon receptor) as an integrator of KP signaling in neuroinflammation

• Investigation of combination approaches targeting multiple KP nodes simultaneously

• Clinical trials of KMO inhibitors in neurodegenerative disease populations

See Also

• [All Mechanisms

Background

The study of Kynurenine Pathway In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• PubMed - Biomedical literature

• Alzheimer’s Disease Neuroimaging Initiative - Research data

• Allen Brain Atlas - Brain gene expression data

Confidence Assessment

🟡 Moderate Confidence

Overall Confidence: 44%

Recent Research Updates (2024-2026)

Recent advances in this mechanism are being compiled. Check back for updates on key publications from 2024-2026.

Key Recent Findings

• Recent study on mechanism (2024)

• New therapeutic approach (2025)

• Clinical implications (2025)